Breast NeoplasmsPhase 4NCT03586154
Combined Intra-articular Shoulder Injection and Stellate Ganglion Block in Chronic Post-mastectomy Shoulder Pain
A Phase 4 study testing Platelet rich plasma and ketamine and bupivacaine injection in people with Breast Neoplasms, run by Mansoura University at 1 site in Egypt.
Trial summary
Background and Purpose: Adhesive capsulitis of the shoulder is commonly found in patients after breast cancer treatment. We aimed to determine the effectiveness of combined shoulder joint intra-articular injection of platelet rich plasma (PRP) with stellate ganglion block (SGB) with ketamine \&bupivacaine injection as… Read more about this study
- Who is it for?
- Ages 18 to 64 years, women only
- Conditions the study is for
- Breast Neoplasms
- What is being tested?
- Platelet rich plasma and ketamine and bupivacaine injection
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 70 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Aug 2017to 2 Apr 2018
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 64 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- post-mastectomy shoulder pain
- age of 18 to less than 65 years
Who cannot join
- refusal to participate
- Patients with acute shoulder pain (trauma, acute postsurgical pain)
- secondary adhesive capsulitis (prior surgery or non-surgically induced states of shoulder affection by adhesive capsulitis)
- hypersensitivity to amide local anesthetics
- general contraindications to SGB and cardiac and hepatic, renal or respiratory failure.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Combined Platelet Rich Plasma Intra-articular Shoulder Injection and Stellate Ganglion Block. A New Technique for Management of Chronic Post-mastectomy Shoulder Pain Syndrome
Background and Purpose: Adhesive capsulitis of the shoulder is commonly found in patients after breast cancer treatment. We aimed to determine the effectiveness of combined shoulder joint intra-articular injection of platelet rich plasma (PRP) with stellate ganglion block (SGB) with ketamine \&bupivacaine injection as a new technique for frozen shoulder (FS) management after mastectomy.
Methods: Sixty four patients with chronic post-mastectomy shoulder pain and stiffness were randomly allocated into one of two groups: group A; ultrasound guided SGB (1 ml ketamine in a dose of 0.5mg/kg plus 5ml bupivacaine 0.5% in total volume 10 ml) and group B; ultrasound guided SGB plus posterior approach shoulder injection with PRP. Visual analogue score (VAS) at rest and at shoulder movement, range of motions (ROM) of shoulder and disability of arm, shoulder and hand (DASH) questionnaire were recorded.
Read the detailed description
Introduction:
Pain after breast surgery is a significant complication and can persist for several months up to years.The most common sites for pain localization are the axilla, medial upper arm and or lateral / anterior chest wall. Pain can be severe enough to cause long-term disabilities leading to shoulder adhesive capsulitis (frozen shoulder) or complex regional pain syndrome. Of course, this could also interfere with daily activities and sleep leading to negative influence on the quality of life of the affected women. Scar formation, protective posture and tension of the soft tissue after surgery can also cause alteration of the shoulder girdle alignment and immobility.
Adhesive capsulitis of the shoulder is commonly found in breast cancer patients with a prevalence can be as high as 86%.Adhesive capsulitis of the shoulder joint is one of the main producers of Post-mastectomy chronic shoulder pain syndrome , the shoulder joint becomes tight due to capsular inflammation resulting in painful and global ROM restriction. Frozen shoulder management has focused around prolonged courses of physiotherapy to maintain shoulder mobility. Corticosteroids and anti-inflammatory medications are also considered as adjuvant therapies in reducing pain and inflammation.
The stellate ganglion is a nerve bundle related to the sympathetic nervous system providing sensation to the upper body. It is present on either side of the trachea at the 7th cervical vertebrae. The stellate ganglion has second and third order neurons that modulate neuropathic pain to the central nervous system and body temperature. The stellate ganglion block (SGB) is mainly indicated for management of chronic neuropathic painful disorders of the head and neck, upper limb, and upper chest by reducing levels of nerve growth factor leading to a decrease in norepinephrine level that plays a fundamental role in pain transmission in these cases. Ketamine enhances the effect of sympathetic blockade with relief of pain, ischaemia and maintains circulation. And so, ketamine is a useful adjuvant to STGB and it clarify the need of permanent destruction of the ganglion by chemical/ radiofrequency neurolysis in patients with peripheral vascular disease.
Recently, platelet-rich plasma (PRP) have been used in treatment of many soft tissue disorders with positive results being rich in several growth factors and other cytokines that can stimulate healing of soft tissues and joints.
In current study, we aimed to clarify the effectiveness of combined intra-articular PRP injection in shoulder joint with SGB over SGB alone in the challenge of management of post-mastectomy chronic shoulder pain.
Patients and methods:
Study design and participants Our study was a randomized controlled double-blind trial conducted in Anesthesia Department of Medical Faculty and Pain Clinics of Mansoura Oncology Center, Egypt during the period from August 2017 till April 2018. The study was accepted by Institutional Research Board of Mansoura University (Code No: R∕ 17.08.44) and followed the 2008 Helsinki declaration ethical standards.
Seventy patients were assessed for eligibility. Six patients were excluded from the study (four did not meet the inclusion criteria and two declined to participate in the study) (Figure 1). Sixty four patients were included with age of 18 to less than 65 ys who showed post-mastectomy shoulder pain.
Exclusion criteria were patient refusal to participate, Patients with acute shoulder pain (trauma, acute postsurgical pain), secondary adhesive capsulitis (prior surgery or non-surgically induced states of shoulder affection by adhesive capsulitis), hypersensitivity to amide local anesthetics, general contraindications to SGB and cardiac and hepatic, renal or respiratory failure. Written informed consents were obtained from individual participants included in the study.
Sample size It was assessed using G-power analysis. Assuming α (type I error) = 0.05 and β (type II error) = 0.2 (power = 80 %) yielded a total sample size of 70.
Randomization Each patient was assigned in a double-blinded manner to one of two groups. Group A (n=32) patients were subjected to ultrasound guided SGB using 1 ml ketamine in a dose of 0.5mg/kg plus 5ml bupivacaine 0.5% in total volume 10 ml.[9] While group B (n=32) patients were subjected to ultrasound guided SGB using ketamine and bupivacaine in the same dose as group A plus posterior approach shoulder injection with PRP.
An individual not involved in the patient care or data collection randomly assigned the patients using Research Randomizer program into two blocks; each of block size 32 was also randomized using two lists of random numbers. Investigators were not allowed to know randomization codes and block size until all calculations and measurements had been entered into the database for all patients. All medical caregivers, investigators and patients were blinded to group allocation. One hour before the injection procedure of an enrolled patient, a nurse (not otherwise participating in the study) opened a sealed opaque envelope containing group allocation, and then filled the assigned drug injection for each patient according to the protocol of randomization. All data were entered in the database before entering the codes of randomization. The principles for intention-to-treat analysis were followed.
Level of evidence:
Level IV, clinical study
Technique Management and Equipment:
All suitable resuscitation drugs (eg. atropine and adrenaline) and equipment's were available including lipid emulsion for local anesthetic toxicity, endotracheal tubes of different sizes, ambo bag, and ventilator. Under strict aseptic technique for place, patients, and instruments, the different blocks technique done in the operative theater with IV access in place, O2 Mask 6L/minute, and full basic monitoring (Noninvasive Blood Pressure Amplifier, pulse oximeter, and ECG) attached, then all patients in this study were monitored throughout the procedure and up to one hour after the block performance.
Stellate ganglion block technique The anterior para-tracheal approach C6 was done. The patient's neck was extended using a pillow under the shoulder while lying in a supine position aiming to keep the esophagus and the transverse process away from each other. Also the patient was asked to open mouth slightly to make the neck muscles more relaxed. Under complete aseptic technique, a linear probe (5-10 MHz) of Siemens Acuson P300 ultrasound machine was initially placed at the cricoid cartilage level. The location of C6 transverse process was determined by the prominent anterior tubercle (Chassaignac's tubercle). Placement of the ultrasound transducer helped to retract the sternocleidomastoid muscle and carotid sheath laterally and the pressure applied by the transducer reduced the distance between the tubercle and skin and to depress the lung dome to avoid occurrence of pneumothorax. A typical sonographic appearance at the C6 level included the anterior tubercle and transverse process of C6, longus capitis muscle, longus colli muscle (LC), carotid artery, and thyroid gland. We inserted a 22-gauge needle and directed towards to the Chassaignac's tubercle then redirected infero-medially towards the body of C6 until reach out of LC muscle while still staying within the prevertebral fascia (figure 2). After negative aspiration for blood and cerebrospinal fluid, ultrasound guided injection of 1 ml ketamine in a dose of 0.5mg/kg plus 5ml bupivacaine 0.5% in total volume 10 ml 10ml volume was used before in a previous study, and was injected in divided doses (injectate volume of 10 ml used to ensure full ganglion blocked and effective spread of the anesthetic agents at the area of the lower cervical sympathetic chain) (figure 3). The solution was allowed to pass caudally toward the stellate ganglion by raising the head of the patient's bed. We confirmed the success of block by the development of Horner's syndrome at side of injection which included ptosis, myosis, facial anhydrosis, enophthalmos and nasal congestion.
Regulations for PRP Preparation:
At the time of treatment, PRP was obtained from a sample of patient's blood. Thirty ml venous blood was drawn to yield 3-5 cc of PRP. Citrate dextrose A (an anticoagulant) was added to prevent platelet activation prior to its use. Preparation of PRP was done by double centrifugation process; an initial centrifugation to separate red blood cells followed by a second centrifugation to concentrate platelets. The whole blood was initially collected in tubes containing anticoagulants. At the initial centrifugation step, whole blood separates into three layers: an upper layer that contains white blood cells and platelets, an intermediate thin layer (buffy coat layer) that is rich in white blood cells, and a bottom layer that consists mostly of red blood cells. For PRP production, both superficial buffy coat and upper layers were transferred to an empty sterile tube. Then the second centrifugation step was done and should be adequate to help in soft pellets formation (erythrocyte platelets) at the bottom of the tube. We removed the upper portion of the volume (platelet-poor plasma). Pellets were homogenized in lower third (5 ml of plasma) to produce PRP.
Posterior approach shoulder injection techniques:
The patient was placed in either the lateral decubitus or sitting position with the ipsilateral hand placed on the contralateral shoulder. The ultrasound probe (frequency 6-13 MHz) was placed just caudal to the acromion over the infraspinatus tendon. The important anatomical points to identify were humeral head, infraspinatus tendon, labrum, and joint capsule. The posterior approach target was between the cartilage of humeral head underneath the capsule and the free edge of labrum. Once the target was obtained, we inserted a 22 gauge needle from lateral to medial direction with in-plane technique (figure 3) then injected PRP.
The two groups were asked to do some stretching exercises at home as finger walk, cross body reach and outward and inward rotations. The patients were explained how to do these exercises and warm up the shoulder before performing the exercises by moist heating pad for 10-15 minutes.
Outcome Variables Primary outcome: Visual analogue score (VAS) was done at rest and at shoulder movement before injection, one, two and three months after injection. VAS was explained to the patients during assessment as 0 equal no pain and 10 equal worst imaginable pain. Shoulder mobility was assessed while the patient was sitting using goniometry. Secondary outcome: 1-ROM was measured in degrees in five position (extension, flexion, and abduction, internal and external rotation) before and one month after injection. 2-Disability of arm, shoulder and hand (DASH) questionnaire was done before injection, one, two and three months after injection.
Statistical analysis:
The collected data were analyzed using Statistical Package of Social Science (SPSS) program for windows (version 16) and Medcalc program. Quantitative parametric data were presented in means and standard deviations (SD) while non-parametric data were presented in median and range. On testing significance of parametric quantitative data, t-test and ANOVA test were used where the later followed by post hoc test. On testing significance of non-parametric data, Mann-Whitny test, Wilcoxon rank test and Kruskal-Wallis test were used where the later followed by post hoc test. Statistically significant results were considered if p value < 0.05. If p values < 0.001, results were considered highly statistically significant.
- Conditions
- Breast Neoplasms
- Being tested
- Platelet rich plasma, ketamine and bupivacaine injection
- Keywords
- Ketamine; pain; platelet rich plasma; mastectomy; shoulder
- Medical subject headings
- Breast Neoplasms, Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Platelet rich plasmaCombination product
Also called PRP
combined platelet rich plasma and 1 ml ketamine in a dose of o.5 ml/kg plus 5ml bupivacaine 0.5% in a total volume 10 ml
ketamine and bupivacaine injectionDrug
1 ml ketamine in a dose of o.5 ml/kg plus 5ml bupivacaine 0.5% in a total volume 10 ml
| Study group | Role | What they receive |
|---|---|---|
| Group A | Other | patients were subjected to ultrasound guided SGB using 1 ml ketamine in a dose of 0.5mg/kg plus 5ml bupivacaine 0.5% in total volume 10 ml Receives: Drug: ketamine and bupivacaine injection |
| Group B | Active comparator | patients were subjected to ultrasound guided SGB using 1 ml ketamine in a dose of 0.5mg/kg plus 5ml bupivacaine 0.5% in total volume 10 ml plus posterior approach shoulder injection with PRP. Receives: Combination Product: Platelet rich plasma; Drug: ketamine and bupivacaine injection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Visual analogue score
Visual analogue score (VAS) was done at rest and at shoulder movement before injection, one, two and three months after injection. VAS was explained to the patients during assessment as 0 equal no pain and 10 equal worst imaginable pain. Shoulder mobility was assessed while the patient was sitting using goniometry.
Measured: Before injection and 1, 2, 3 months after injection
Secondary outcomes (2)
Range of motion
It was measured in degrees in five position (extension, flexion, and abduction, internal and external rotation) before and one month after injection.
Measured: Before injection and one month after injection
Disability of arm
shoulder and hand (DASH) questionnaire was done before injection, one, two and three months after injection.
Measured: Before injection and 1, 2 , 3 months after injection
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jul 2018
- Study start1 Aug 2017
- Primary completion2 Jan 2018
- Study completion2 Apr 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (11)Papers the sponsor has linked to this study.
- Other trials for Breast NeoplasmsStudies of the same condition, open and under way.
- More trials run by Mansoura UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 70 participants (actual)
Sponsor and investigators
- Lead sponsor
- Mansoura University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Nevert Adel, Mansoura University
- Investigators
- Mohamed Tahan, MD, Principal investigator, Professor of Anesthesia, Medical Faculty, Mansoura University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03586154
- Sponsor's protocol ID
- MansouraU Nevert
- Status last verified
- Jul 2018
- First submitted
- 29 Jun 2018
- Last updated
- 16 Jul 2018
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Macdonald L, Bruce J, Scott NW, Smith WC, Chambers WA. Long-term follow-up of breast cancer survivors with post-mastectomy pain syndrome. Br J Cancer. 2005 Jan 31;92(2):225-30. doi: 10.1038/sj.bjc.6602304.
PubMed 15655557Waltho D, Rockwell G. Post-breast surgery pain syndrome: establishing a consensus for the definition of post-mastectomy pain syndrome to provide a standardized clinical and research approach - a review of the literature and discussion. Can J Surg. 2016 Sep;59(5):342-50. doi: 10.1503/cjs.000716.
PubMed 27668333Ebaugh D, Spinelli B, Schmitz KH. Shoulder impairments and their association with symptomatic rotator cuff disease in breast cancer survivors. Med Hypotheses. 2011 Oct;77(4):481-7. doi: 10.1016/j.mehy.2011.06.015. Epub 2011 Jul 18.
PubMed 21764521Leonidou A, Woods DA. A preliminary study of manipulation under anaesthesia for secondary frozen shoulder following breast cancer treatment. Ann R Coll Surg Engl. 2014 Mar;96(2):111-5. doi: 10.1308/003588414X13824511649652.
PubMed 24780667Yang S, Park DH, Ahn SH, Kim J, Lee JW, Han JY, Kim DK, Jeon JY, Choi KH, Kim W. Prevalence and risk factors of adhesive capsulitis of the shoulder after breast cancer treatment. Support Care Cancer. 2017 Apr;25(4):1317-1322. doi: 10.1007/s00520-016-3532-4. Epub 2016 Dec 9.
PubMed 27942856Aslani H, Nourbakhsh ST, Zafarani Z, Ahmadi-Bani M, Ananloo ME, Beigy M, Salehi S. Platelet-Rich Plasma for Frozen Shoulder: A Case Report. Arch Bone Jt Surg. 2016 Jan;4(1):90-3.
PubMed 26894228Lipov EG, Joshi JR, Sanders S, Slavin KV. A unifying theory linking the prolonged efficacy of the stellate ganglion block for the treatment of chronic regional pain syndrome (CRPS), hot flashes, and posttraumatic stress disorder (PTSD). Med Hypotheses. 2009 Jun;72(6):657-61. doi: 10.1016/j.mehy.2009.01.009. Epub 2009 Feb 23.
PubMed 19237252Smith PA. Intra-articular Autologous Conditioned Plasma Injections Provide Safe and Efficacious Treatment for Knee Osteoarthritis: An FDA-Sanctioned, Randomized, Double-blind, Placebo-controlled Clinical Trial. Am J Sports Med. 2016 Apr;44(4):884-91. doi: 10.1177/0363546515624678. Epub 2016 Feb 1.
PubMed 26831629Peng PW, Cheng P. Ultrasound-guided interventional procedures in pain medicine: a review of anatomy, sonoanatomy, and procedures. Part III: shoulder. Reg Anesth Pain Med. 2011 Nov-Dec;36(6):592-605. doi: 10.1097/AAP.0b013e318231e068.
PubMed 22005657Stubblefield MD, Custodio CM. Upper-extremity pain disorders in breast cancer. Arch Phys Med Rehabil. 2006 Mar;87(3 Suppl 1):S96-9; quiz S100-1. doi: 10.1016/j.apmr.2005.12.017.
PubMed 16500198Kulkarni KR, Kadam AI, Namazi IJ. Efficacy of stellate ganglion block with an adjuvant ketamine for peripheral vascular disease of the upper limbs. Indian J Anaesth. 2010 Nov;54(6):546-51. doi: 10.4103/0019-5049.72645.
PubMed 21224973
Study at a glance
From the registry record, last updated by the sponsor on 16 Jul 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Combined Platelet Rich Plasma Intra-articular Shoulder Injection and Stellate Ganglion Block. A New Technique for Management of Chronic Post-mastectomy Shoulder Pain Syndrome
- ClinicalTrials.gov ID
- NCT03586154
- Acronym / sponsor ID
- MansouraU Nevert
- Conditions
- Breast Neoplasms
- Keywords
- Ketamine; pain; platelet rich plasma; mastectomy; shoulder
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 70 participants (actual)
- Lead sponsor
- Mansoura UniversityUniversity, hospital or other
- Study start
- 1 Aug 2017 (actual)
- Primary completion
- 2 Jan 2018 (actual)
- Study completion
- 2 Apr 2018 (actual)
- First posted
- 13 Jul 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background and Purpose: Adhesive capsulitis of the shoulder is commonly found in patients after breast cancer treatment. We aimed to determine the effectiveness of combined shoulder joint intra-articular injection of platelet rich plasma (PRP) with stellate ganglion block (SGB) with ketamine \&bupivacaine injection as a new technique for frozen shoulder (FS) management after mastectomy.
Methods: Sixty four patients with chronic post-mastectomy shoulder pain and stiffness were randomly allocated into one of two groups: group A; ultrasound guided SGB (1 ml ketamine in a dose of 0.5mg/kg plus 5ml bupivacaine 0.5% in total volume 10 ml) and group B; ultrasound guided SGB plus posterior approach shoulder injection with PRP. Visual analogue score (VAS) at rest and at shoulder movement, range of motions (ROM) of shoulder and disability of arm, shoulder and hand (DASH) questionnaire were recorded.
Detailed description
Introduction:
Pain after breast surgery is a significant complication and can persist for several months up to years.The most common sites for pain localization are the axilla, medial upper arm and or lateral / anterior chest wall. Pain can be severe enough to cause long-term disabilities leading to shoulder adhesive capsulitis (frozen shoulder) or complex regional pain syndrome. Of course, this could also interfere with daily activities and sleep leading to negative influence on the quality of life of the affected women. Scar formation, protective posture and tension of the soft tissue after surgery can also cause alteration of the shoulder girdle alignment and immobility.
Adhesive capsulitis of the shoulder is commonly found in breast cancer patients with a prevalence can be as high as 86%.Adhesive capsulitis of the shoulder joint is one of the main producers of Post-mastectomy chronic shoulder pain syndrome , the shoulder joint becomes tight due to capsular inflammation resulting in painful and global ROM restriction. Frozen shoulder management has focused around prolonged courses of physiotherapy to maintain shoulder mobility. Corticosteroids and anti-inflammatory medications are also considered as adjuvant therapies in reducing pain and inflammation.
The stellate ganglion is a nerve bundle related to the sympathetic nervous system providing sensation to the upper body. It is present on either side of the trachea at the 7th cervical vertebrae. The stellate ganglion has second and third order neurons that modulate neuropathic pain to the central nervous system and body temperature. The stellate ganglion block (SGB) is mainly indicated for management of chronic neuropathic painful disorders of the head and neck, upper limb, and upper chest by reducing levels of nerve growth factor leading to a decrease in norepinephrine level that plays a fundamental role in pain transmission in these cases. Ketamine enhances the effect of sympathetic blockade with relief of pain, ischaemia and maintains circulation. And so, ketamine is a useful adjuvant to STGB and it clarify the need of permanent destruction of the ganglion by chemical/ radiofrequency neurolysis in patients with peripheral vascular disease.
Recently, platelet-rich plasma (PRP) have been used in treatment of many soft tissue disorders with positive results being rich in several growth factors and other cytokines that can stimulate healing of soft tissues and joints.
In current study, we aimed to clarify the effectiveness of combined intra-articular PRP injection in shoulder joint with SGB over SGB alone in the challenge of management of post-mastectomy chronic shoulder pain.
Patients and methods:
Study design and participants Our study was a randomized controlled double-blind trial conducted in Anesthesia Department of Medical Faculty and Pain Clinics of Mansoura Oncology Center, Egypt during the period from August 2017 till April 2018. The study was accepted by Institutional Research Board of Mansoura University (Code No: R∕ 17.08.44) and followed the 2008 Helsinki declaration ethical standards.
Seventy patients were assessed for eligibility. Six patients were excluded from the study (four did not meet the inclusion criteria and two declined to participate in the study) (Figure 1). Sixty four patients were included with age of 18 to less than 65 ys who showed post-mastectomy shoulder pain.
Exclusion criteria were patient refusal to participate, Patients with acute shoulder pain (trauma, acute postsurgical pain), secondary adhesive capsulitis (prior surgery or non-surgically induced states of shoulder affection by adhesive capsulitis), hypersensitivity to amide local anesthetics, general contraindications to SGB and cardiac and hepatic, renal or respiratory failure. Written informed consents were obtained from individual participants included in the study.
Sample size It was assessed using G-power analysis. Assuming α (type I error) = 0.05 and β (type II error) = 0.2 (power = 80 %) yielded a total sample size of 70.
Randomization Each patient was assigned in a double-blinded manner to one of two groups. Group A (n=32) patients were subjected to ultrasound guided SGB using 1 ml ketamine in a dose of 0.5mg/kg plus 5ml bupivacaine 0.5% in total volume 10 ml.[9] While group B (n=32) patients were subjected to ultrasound guided SGB using ketamine and bupivacaine in the same dose as group A plus posterior approach shoulder injection with PRP.
An individual not involved in the patient care or data collection randomly assigned the patients using Research Randomizer program into two blocks; each of block size 32 was also randomized using two lists of random numbers. Investigators were not allowed to know randomization codes and block size until all calculations and measurements had been entered into the database for all patients. All medical caregivers, investigators and patients were blinded to group allocation. One hour before the injection procedure of an enrolled patient, a nurse (not otherwise participating in the study) opened a sealed opaque envelope containing group allocation, and then filled the assigned drug injection for each patient according to the protocol of randomization. All data were entered in the database before entering the codes of randomization. The principles for intention-to-treat analysis were followed.
Level of evidence:
Level IV, clinical study
Technique Management and Equipment:
All suitable resuscitation drugs (eg. atropine and adrenaline) and equipment's were available including lipid emulsion for local anesthetic toxicity, endotracheal tubes of different sizes, ambo bag, and ventilator. Under strict aseptic technique for place, patients, and instruments, the different blocks technique done in the operative theater with IV access in place, O2 Mask 6L/minute, and full basic monitoring (Noninvasive Blood Pressure Amplifier, pulse oximeter, and ECG) attached, then all patients in this study were monitored throughout the procedure and up to one hour after the block performance.
Stellate ganglion block technique The anterior para-tracheal approach C6 was done. The patient's neck was extended using a pillow under the shoulder while lying in a supine position aiming to keep the esophagus and the transverse process away from each other. Also the patient was asked to open mouth slightly to make the neck muscles more relaxed. Under complete aseptic technique, a linear probe (5-10 MHz) of Siemens Acuson P300 ultrasound machine was initially placed at the cricoid cartilage level. The location of C6 transverse process was determined by the prominent anterior tubercle (Chassaignac's tubercle). Placement of the ultrasound transducer helped to retract the sternocleidomastoid muscle and carotid sheath laterally and the pressure applied by the transducer reduced the distance between the tubercle and skin and to depress the lung dome to avoid occurrence of pneumothorax. A typical sonographic appearance at the C6 level included the anterior tubercle and transverse process of C6, longus capitis muscle, longus colli muscle (LC), carotid artery, and thyroid gland. We inserted a 22-gauge needle and directed towards to the Chassaignac's tubercle then redirected infero-medially towards the body of C6 until reach out of LC muscle while still staying within the prevertebral fascia (figure 2). After negative aspiration for blood and cerebrospinal fluid, ultrasound guided injection of 1 ml ketamine in a dose of 0.5mg/kg plus 5ml bupivacaine 0.5% in total volume 10 ml 10ml volume was used before in a previous study, and was injected in divided doses (injectate volume of 10 ml used to ensure full ganglion blocked and effective spread of the anesthetic agents at the area of the lower cervical sympathetic chain) (figure 3). The solution was allowed to pass caudally toward the stellate ganglion by raising the head of the patient's bed. We confirmed the success of block by the development of Horner's syndrome at side of injection which included ptosis, myosis, facial anhydrosis, enophthalmos and nasal congestion.
Regulations for PRP Preparation:
At the time of treatment, PRP was obtained from a sample of patient's blood. Thirty ml venous blood was drawn to yield 3-5 cc of PRP. Citrate dextrose A (an anticoagulant) was added to prevent platelet activation prior to its use. Preparation of PRP was done by double centrifugation process; an initial centrifugation to separate red blood cells followed by a second centrifugation to concentrate platelets. The whole blood was initially collected in tubes containing anticoagulants. At the initial centrifugation step, whole blood separates into three layers: an upper layer that contains white blood cells and platelets, an intermediate thin layer (buffy coat layer) that is rich in white blood cells, and a bottom layer that consists mostly of red blood cells. For PRP production, both superficial buffy coat and upper layers were transferred to an empty sterile tube. Then the second centrifugation step was done and should be adequate to help in soft pellets formation (erythrocyte platelets) at the bottom of the tube. We removed the upper portion of the volume (platelet-poor plasma). Pellets were homogenized in lower third (5 ml of plasma) to produce PRP.
Posterior approach shoulder injection techniques:
The patient was placed in either the lateral decubitus or sitting position with the ipsilateral hand placed on the contralateral shoulder. The ultrasound probe (frequency 6-13 MHz) was placed just caudal to the acromion over the infraspinatus tendon. The important anatomical points to identify were humeral head, infraspinatus tendon, labrum, and joint capsule. The posterior approach target was between the cartilage of humeral head underneath the capsule and the free edge of labrum. Once the target was obtained, we inserted a 22 gauge needle from lateral to medial direction with in-plane technique (figure 3) then injected PRP.
The two groups were asked to do some stretching exercises at home as finger walk, cross body reach and outward and inward rotations. The patients were explained how to do these exercises and warm up the shoulder before performing the exercises by moist heating pad for 10-15 minutes.
Outcome Variables Primary outcome: Visual analogue score (VAS) was done at rest and at shoulder movement before injection, one, two and three months after injection. VAS was explained to the patients during assessment as 0 equal no pain and 10 equal worst imaginable pain. Shoulder mobility was assessed while the patient was sitting using goniometry. Secondary outcome: 1-ROM was measured in degrees in five position (extension, flexion, and abduction, internal and external rotation) before and one month after injection. 2-Disability of arm, shoulder and hand (DASH) questionnaire was done before injection, one, two and three months after injection.
Statistical analysis:
The collected data were analyzed using Statistical Package of Social Science (SPSS) program for windows (version 16) and Medcalc program. Quantitative parametric data were presented in means and standard deviations (SD) while non-parametric data were presented in median and range. On testing significance of parametric quantitative data, t-test and ANOVA test were used where the later followed by post hoc test. On testing significance of non-parametric data, Mann-Whitny test, Wilcoxon rank test and Kruskal-Wallis test were used where the later followed by post hoc test. Statistically significant results were considered if p value < 0.05. If p values < 0.001, results were considered highly statistically significant.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group A | Other | Drug: ketamine and bupivacaine injectionpatients were subjected to ultrasound guided SGB using 1 ml ketamine in a dose of 0.5mg/kg plus 5ml bupivacaine 0.5% in total volume 10 ml |
| Group B | Active comparator | Combination Product: Platelet rich plasma, Drug: ketamine and bupivacaine injectionpatients were subjected to ultrasound guided SGB using 1 ml ketamine in a dose of 0.5mg/kg plus 5ml bupivacaine 0.5% in total volume 10 ml plus posterior approach shoulder injection with PRP. |
Who may qualify
- Ages
- 18 to 64 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- post-mastectomy shoulder pain
- age of 18 to less than 65 years
Key exclusion criteria (5 listed)
- refusal to participate
- Patients with acute shoulder pain (trauma, acute postsurgical pain)
- secondary adhesive capsulitis (prior surgery or non-surgically induced states of shoulder affection by adhesive capsulitis)
- hypersensitivity to amide local anesthetics
- general contraindications to SGB and cardiac and hepatic, renal or respiratory failure.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Platelet rich plasmaAlso: PRPcombined platelet rich plasma and 1 ml ketamine in a dose of o.5 ml/kg plus 5ml bupivacaine 0.5% in a total volume 10 ml | Combination product | Group B |
| ketamine and bupivacaine injection1 ml ketamine in a dose of o.5 ml/kg plus 5ml bupivacaine 0.5% in a total volume 10 ml | Drug | Group A, Group B |
Primary outcome
Visual analogue score
Time frame: Before injection and 1, 2, 3 months after injection
Visual analogue score (VAS) was done at rest and at shoulder movement before injection, one, two and three months after injection. VAS was explained to the patients during assessment as 0 equal no pain and 10 equal worst imaginable pain. Shoulder mobility was assessed while the patient was sitting using goniometry.
2 secondary outcomes
Range of motion
Time frame: Before injection and one month after injection
Disability of arm
Time frame: Before injection and 1, 2 , 3 months after injection
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jul 2018.
- Background: PubMed 15655557Macdonald L, Bruce J, Scott NW, Smith WC, Chambers WA. Long-term follow-up of breast cancer survivors with post-mastectomy pain syndrome. Br J Cancer. 2005 Jan 31;92(2):225-30. doi: 10.1038/sj.bjc.6602304.
- Background: PubMed 27668333Waltho D, Rockwell G. Post-breast surgery pain syndrome: establishing a consensus for the definition of post-mastectomy pain syndrome to provide a standardized clinical and research approach - a review of the literature and discussion. Can J Surg. 2016 Sep;59(5):342-50. doi: 10.1503/cjs.000716.
- Background: PubMed 21764521Ebaugh D, Spinelli B, Schmitz KH. Shoulder impairments and their association with symptomatic rotator cuff disease in breast cancer survivors. Med Hypotheses. 2011 Oct;77(4):481-7. doi: 10.1016/j.mehy.2011.06.015. Epub 2011 Jul 18.
- Background: PubMed 24780667Leonidou A, Woods DA. A preliminary study of manipulation under anaesthesia for secondary frozen shoulder following breast cancer treatment. Ann R Coll Surg Engl. 2014 Mar;96(2):111-5. doi: 10.1308/003588414X13824511649652.
- Background: PubMed 27942856Yang S, Park DH, Ahn SH, Kim J, Lee JW, Han JY, Kim DK, Jeon JY, Choi KH, Kim W. Prevalence and risk factors of adhesive capsulitis of the shoulder after breast cancer treatment. Support Care Cancer. 2017 Apr;25(4):1317-1322. doi: 10.1007/s00520-016-3532-4. Epub 2016 Dec 9.
- Background: PubMed 26894228Aslani H, Nourbakhsh ST, Zafarani Z, Ahmadi-Bani M, Ananloo ME, Beigy M, Salehi S. Platelet-Rich Plasma for Frozen Shoulder: A Case Report. Arch Bone Jt Surg. 2016 Jan;4(1):90-3.
- Background: PubMed 19237252Lipov EG, Joshi JR, Sanders S, Slavin KV. A unifying theory linking the prolonged efficacy of the stellate ganglion block for the treatment of chronic regional pain syndrome (CRPS), hot flashes, and posttraumatic stress disorder (PTSD). Med Hypotheses. 2009 Jun;72(6):657-61. doi: 10.1016/j.mehy.2009.01.009. Epub 2009 Feb 23.
- Background: PubMed 26831629Smith PA. Intra-articular Autologous Conditioned Plasma Injections Provide Safe and Efficacious Treatment for Knee Osteoarthritis: An FDA-Sanctioned, Randomized, Double-blind, Placebo-controlled Clinical Trial. Am J Sports Med. 2016 Apr;44(4):884-91. doi: 10.1177/0363546515624678. Epub 2016 Feb 1.
- Background: PubMed 22005657Peng PW, Cheng P. Ultrasound-guided interventional procedures in pain medicine: a review of anatomy, sonoanatomy, and procedures. Part III: shoulder. Reg Anesth Pain Med. 2011 Nov-Dec;36(6):592-605. doi: 10.1097/AAP.0b013e318231e068.
- Background: PubMed 16500198Stubblefield MD, Custodio CM. Upper-extremity pain disorders in breast cancer. Arch Phys Med Rehabil. 2006 Mar;87(3 Suppl 1):S96-9; quiz S100-1. doi: 10.1016/j.apmr.2005.12.017.
- Background: PubMed 21224973Kulkarni KR, Kadam AI, Namazi IJ. Efficacy of stellate ganglion block with an adjuvant ketamine for peripheral vascular disease of the upper limbs. Indian J Anaesth. 2010 Nov;54(6):546-51. doi: 10.4103/0019-5049.72645.
- Ultrasound Guided Stellate Ganglion Block in Postmastectomy Pain Syndrome: A Comparison of Ketamine versus Morphine as Adjuvant to BupivacaineLink provided by the sponsor.
- Urbaniak GC, Plous S. Research randomizer. Retrieved July. 1997;7:2008.Link provided by the sponsor.
- Sweeny J, Grossman BJ. Blood collection, storage and component preparation methods. Tech Manual 14th ed Bethesda MD Am Assoc Blood Banks. 2002;955-8.Link provided by the sponsor.
- Welsh WJ. Autologous platelet gel: clinical function and usage in plastic surgery. Cosmet Derm. 2000;11:13.Link provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Breast Neoplasms
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mohamed Tahan, MD principal investigator
Professor of Anesthesia, Medical Faculty, Mansoura University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Platelet rich plasma and ketamine and bupivacaine injection in people with Breast Neoplasms, run by Mansoura University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Jul 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Visual analogue score (time frame: Before injection and 1, 2, 3 months after injection). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03586154, which also lists 11 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2018.